Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA)
Last day of trading in BTA in Alligator Bioscience AB ("Alligator" or the “Company") will be Friday February 26, 2021 and stop d ...
Alligator Bioscience’s rights issue oversubscribed
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...
Larger shareholder and board member transfer subscription rights free of charge to qualified investors
The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the autho ...
Alligator Bioscience appoints Chief Scientific Officer
Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark ...
The subscription period in Alligator Bioscience’s rights issue commences today
Today is the first day of the subscription period in Alligator Bioscience AB (publ)’s (“Alligator” or the “Company”) rights issue of shares ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has, in connection with the rights i ...
Alligator Bioscience recruits new Chief Medical Officer
Lund, Sweden, December 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina ...
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
Lund, Sweden, December 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial ...